

# An health technology assessments study of gene therapies with the focus on cost-effectiveness models

Giorgia Gambarelli

University of Uniroma1 La Sapienza, Rome

## Abstract

### Background:

Gene therapies are an innovative strategy for treating genetic disorders; however, they are still emerging on the market access and in the healthcare system. Significant differences can be seen during HTAs carried out in various countries since Health technology assessment (HTA) agencies have not yet elaborated any standardized approach for assessing gene therapies. We focused on submitted economic models of gene therapies approved for use by the US FDA and EMA with the aim to provide a comprehensive summary of how selected HTA bodies assessed the cost-effectiveness of gene therapies.

**Received:** August 07, 2022; **Accepted:** August 14, 2022; **Published:** August 29, 2022

## Biography

Giorgia Gambarelli is a chief hospital pharmacist in Policlinico Umberto Primo University Teaching Hospital in Rome. She cooperates with local and regional formulary Committees and cooperates with AIFA at national level. She cooperates with the Ministry of Health General Department for Medical Devices. She teaches Pharmacoeconomic assessments in Specialization School of Hospital Pharmacy, University

of Uniroma1 La Sapiens in Rome.

Dr Giovanna Gambarelli is a chief hospital pharmacist in S. Eugenio academic general hospital and takes part to local and regional formulary Committees, cooperates with AIFA at national level, cooperates with the Ministry of Health General Department for Medical Devices as well. She teaches Epidemiology and prescriptive appropriateness in Specialization School of Hospital Pharmacy, University of Uniroma1 La Sapienza in Rome.